
Geistlich Derma-Gide®
Expect Performance
In an IRB approved 10-patient retrospective study¹, the authors assessed the clinical effectiveness and healing characteristics of the Geistlich Derma- Gide®. Additional data was collected on the average cost to treat each patient as well as unique handling and performance characteristics of the product.
Continuous Clinical Research
Geistlich has a long history of clinical research supporting the effectiveness and performance of their products.
Ongoing research:
- Randomized controlled prospective clinical study to compare Geistlich Derma-Gide® vs Standard of Care in the treatment of Diabetic Foot Ulcers
Patient information: 63-year-old Female with Diabetes mellitus
2 cm × 2 cm plantar Diabetic Foot Ulcer with wound edge maceration and exposed cartilage and tendon | Wagner grade 2 | 6 months of unsuccessful treatment with Standard of Care | Healing after 4 weeks of Geistlich Derma-Gide® treatment
Patient information: 43-year-old Male with Diabetes mellitus
5 cm × 3 cm distal Diabetic Foot Ulcer with exposed bones | Wagner grade 2 | Two months of unsuccessful treatment with Standard of Care | Significant progression/healing after 6 weeks of Geistlich Derma-Gide® treatment
Reference:
- Data on file
Cookie-Settings
We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.
Necessary cookies
These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
Statistics cookies
These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.
Marketing cookies
These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.